Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809674 | 0.88 | OPRM1 (0.44) | HTR2CADAM17OPRM1 | |
| SCHEMBL4813860 | 0.88 | MEN1 (0.42) | HTR2C | |
| SCHEMBL6060415 | 0.88 | HTR2C (0.36) | HTR2CCYP3A4CYP2C19OPRM1ALDH1A1 | |
| SCHEMBL4815711 | 0.87 | TDP1 (0.44) | HTR2CADAM17CYP2C19KDM4EHPGD | |
| SCHEMBL4808679 | 0.84 | HTR2C (0.36) | HTR2COPRM1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4813911 | 0.84 | HTR2C (0.46) | HTR2C | |
| SCHEMBL4812586 | 0.82 | HTR2C (0.42) | HTR2CADAM17ALDH1A1MAPT | |
| SCHEMBL4808284 | 0.81 | HTR2C (0.46) | HTR2CADAM17CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4815646 | 0.81 | SMN1; SMN2 (0.41) | HTR2CADAM17ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27635050 | 0.79 | HTR2C (0.47) | HTR2CADAM17CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2006045246-A1 | CYCLOPENTANE CARBOXYLATE COMPOUNDS, PROCESS AND INTERMEDIATES FOR PREPARING THE SAME AND USE THEREOF | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | HTR2C 3278/4885ADAM17 2714/4885CYP3A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.